Member Directory

Asahi Kasei Pharma

Please watch our video about our open innovation program here https://www.youtube.com/watch?v=rWPkQAae-Cc
Astellas Pharma Europe Ltd
Astex Pharmaceuticals Ltd

Astex is dedicated to the discovery and development of novel small molecule therapeutics with a primary focus on oncology. The Company, which is a recognised leader in the field of Fragment Based Drug Discovery, is developing a proprietary pipeline of novel therapies and has a number of other programmes partnered with major pharmaceutical companies with products in clinical development. . . In October 2013, Astex was acquired by Otsuka Pharmaceutical Co. Ltd., Tokyo, Japan. . . For more information about Astex please visit http://www.astx.com
AstraZeneca

AstraZeneca is a global, innovation-driven, integrated biopharmaceutical company.. . We discover, develop, manufacture and market prescription medicines for six important areas of healthcare, which include some of the world’s most serious illnesses: cancer, cardiovascular, gastrointestinal, infection, neuroscience, and respiratory and inflammation.. . We employ over 61,000 people (46% in Europe, 24% in the North America, 7% in Latin America and 24% in Asia, Africa and Australasia)
Atar Advisors Limited
ATG Scientific Ltd
Aviadobio Limited

At AviadoBio, our mission is to transform the lives of people living with neurodegenerative disorders by developing and delivering transformative gene therapies for diseases including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The Company’s technology is based on pioneering research from King’s College London and the UK Dementia Research Institute. AviadoBio’s unique platform combines next-generation gene therapy design with deep neuroscience expertise and a novel neuroanatomy-led approach to drug delivery.

AviadoBio’s investors include New Enterprise Associates (NEA), Monograph Capital, Advent Life Sciences, EQT Lifesciences, Dementia Discovery Fund (DDF), F-Prime Capital, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), and LifeArc.

The company is developing AVB-101 for patients with FTD-GRN. AVB-101 is an investigational AAV gene therapy designed to slow or stop disease progression by delivering a functional copy of the GRN gene throughout the central nervous system to restore progranulin levels.

Pages